Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8232985 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 6 Pages |
Abstract
Despite the reduction in total dose from 66 Gy to 54 Gy, control of locoregional disease and survival with CHART were similar to those with CRT. These findings, together with the low incidence of long-term severe adverse events, suggest that CHART is a treatment option for patients with low-risk disease and for those unable to withstand the toxicity of concurrent chemoradiotherapy.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Michele I. M.D., Ana M. Ph.D., Mahesh K.B. Ph.D., Stanley M.D., CHART Trial Collaborators CHART Trial Collaborators,